Reimbursement, Patient Switches Create Entry Point For Vanda’s Fanapt
Executive Summary
Launching a "me too" product with a serious safety risk in a crowded field is not an easy task. But with the right profile and the right expectations, Vanda may have found the perfect entry point for its atypical antipsychotic Fanapt (iloperidone)
You may also be interested in...
Novartis Deal Sealed, Vanda Plays Up Injectable Potential
Vanda turns near-rags to riches selling Fanapt rights back to the originator, a rare feat for a drug in-licensed from Big Pharma.
Atypical Antipsychotic Market Snapshot: Making Way For Three New Drugs
Three newly-approved drugs - Schering Plough's Saphris, Johnson & Johnson's Invega Sustenna and Vanda's Fanapt - are poised to enter the atypical antipsychotic space despite the crowd of approved products and the specter of market genericization
Atypical Antipsychotic Market Snapshot: Making Way For Three New Drugs
Three newly-approved drugs - Schering Plough's Saphris, Johnson & Johnson's Invega Sustenna and Vanda's Fanapt - are poised to enter the atypical antipsychotic space despite the crowd of approved products and the specter of market genericization